Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.

Novel cisplatin nanoparticle safe as adjunctive treatment for solid tumours

11 Jan 2018

Use of NC-6004, a novel cisplatin nanoparticle developed using micellar technology, as an adjunct to gemcitabine in the treatment of patients with advanced solid tumours appears to be well tolerated, and greater equivalent doses of cisplatin are achieved with no clinically significant neurotoxicity, ototoxicity or nephrotoxicity, as shown in a recent study.

A total of 22 patients with advanced solid tumours were given NC-6004 at 60–180 mg/m2 on day 1 and gemcitabine at 1,250 mg/m2 on days 1 and 8 every 3 weeks. Dose escalation of NC-6004 was initiated with a single patient run-in until a dose-limiting toxicity occurred at 180 mg/m2.

There were four cohorts of four patients enrolled at doses predicted by the Bayesian continual reassessment model (N-CRM). Maximum tolerated dose (MTD) was defined as having the greatest probability of target toxicity <25 percent. Quality of life was evaluated using the EORTC-QLQ-C30.

The most commonly reported grade III/IV haematologic adverse events were leukopaenia (68 percent) and thrombocytopaenia (59 percent). Of the 20 pretreated patients evaluable for response, 10 had previous exposure to a platinum agent. The MTD was 135 mg/m2.

A total of nine patients were treated at MTD, with treatment lasting a median of 15 weeks (range, 3–50). There were 11 patients (55 percent) who showed tumour shrinkage, three patients (15 percent) who had partial responses, and 14 patients (70 percent) who achieved stable disease.

EORTC QLC-C30 scores improved or remained stable in most patients.

The present data demonstrate the tolerability and promising activity of NC-6004 in combination with gemcitabine, researchers said, adding that the combination warrants further investigation in phase II trials enrolling nonsmall cell lung cancer, biliary tract and bladder cancer patients.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, Yesterday
First-line therapy with the BTK* inhibitor ibrutinib plus the anti-CD20 immunotherapy rituximab confers significant survival advantage over the current gold-standard regimen of fludarabine, cyclophosphamide, and rituximab (FCR) for young, fit patients with treatment-naïve chronic lymphocytic leukaemia (CLL), according to the E1912 trial, a large cooperative group study supported by the US National Cancer Institute.
Rachel Soon, 05 Dec 2018

At the recent Malaysian Community Pharmacy Business Forum (MyCPBF), a discussion forum was held on the subject of “Transcending Primary Healthcare Services: The Future of Specialized Pharmacy Services and Pharmacy Specialization”.

Dr Renly Lim, 01 Aug 2018
Palliative care uses an integrated, multidisciplinary approach to reduce suffering and to improve the quality of life of patients battling with life-threatening illnesses.
Rachel Soon, 01 Mar 2018

Over half of consumers who use herbal supplements still do not inform physicians of their practices in consultation, according to a local study.